Just the dudes gathered to talk about the JAMA Internal Medicine Meta Analysis on Gadolinium in CKD stage 4 and 5.

Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast AgentA Systematic Review and Meta-analysis.

Summary on NephJC

Cast:

Joel Topf

Swapnil Hiremath

Matt Sparks

Show Notes:

Swap has a disclosure!

Grobner’s original paper reporting the association between gadolinium and NSF.

Matt’s article on alternatives to gadolinium in MRI:

Diagnostic value of alternative techniques to gadolinium-based contrast agents in MR neuroimaging—a comprehensive overview

Using Ferumoxytol as an MRI contrast agent.

Saurabh Jha’s editorial (@RogueRad) for NephMadness when Gadolinium in CKD 4 was a team in 2018.

PEXIVAS was an abstract in 2018 and was not published until 2020.

A Cultural History of Rock-Paper-Scissors

Michelle’s recent case of NSF in a child (in case you thought this disease was gone)

The most recent case report (2019) was a 14 year old girl with primary hyperoxaluria on peritoneal dialysis who received gadolinium for MRI to rule out PE. She developed NSF within 3 months. #NephJC https://t.co/ngfIDr6QGH pic.twitter.com/XjPwUIDBA9
— Michelle Rheault (@rheault_m) January 28, 2020

Removing Gad with dialysis.